Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 14,656 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 14,656 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $12.29, for a total value of $180,122.24. Following the sale, the chief executive officer now directly owns 261,361 shares of the company’s stock, valued at approximately $3,212,126.69. This represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Thursday, March 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $16.69, for a total transaction of $917,950.00.
• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00.

Centessa Pharmaceuticals Stock Up 4.3 %

CNTA opened at $12.67 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -8.28 and a beta of 1.53. Centessa Pharmaceuticals plc has a one year low of $7.75 and a one year high of $19.09. The business’s fifty day moving average is $14.62 and its two-hundred day moving average is $15.92.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. Analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on CNTA shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Piper Sandler began coverage on Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an “overweight” rating and a $38.00 price target on the stock. TD Cowen assumed coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $27.71.

Institutional Trading of Centessa Pharmaceuticals

Several large investors have recently modified their holdings of CNTA. Janus Henderson Group PLC raised its position in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC acquired a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth $20,994,000. Franklin Resources Inc. lifted its position in shares of Centessa Pharmaceuticals by 99.1% in the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after acquiring an additional 1,145,823 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Centessa Pharmaceuticals by 26.2% in the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after purchasing an additional 710,936 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.